Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
Background. Opioid use disorder (OUD) in pregnancy is managed by medication-assisted treatment. Sublingual buprenorphine is one option, but subcutaneous extended-release buprenorphine (Sublocade®) is an alternate form administered in monthly injections. Through an extensive literature search, we did...
Saved in:
Main Authors: | Craig V. Towers, Heather Deisher |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Obstetrics and Gynecology |
Online Access: | http://dx.doi.org/10.1155/2020/3127676 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: Local anesthesia with lidocaine infiltration for extended-release buprenorphine therapy
by: Pouya Azar, et al.
Published: (2025-01-01) -
Patients' perspectives on buprenorphine subcutaneous implant: a case series
by: Claudio Pierlorenzi, et al.
Published: (2024-04-01) -
Correction: Patients’ perspectives on buprenorphine subcutaneous implant: a case series
by: Claudio Pierlorenzi, et al.
Published: (2025-02-01) -
Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine
by: Oscar D’Agnone
Published: (2019-01-01) -
Buprenorphine and its formulations: a comprehensive review
by: Salomon Poliwoda, et al.
Published: (2022-08-01)